DASHENLIN PHARMACEUTICAL GROUP CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 21.2 CNY | +2.27% |
|
-5.02% | -14.86% |
| Mar. 18 | Dashenlin Pharmaceutical to Buy Back Up to 200 Million Yuan Shares | MT |
| Mar. 05 | Dashenlin Pharmaceutical Plans to Buy Back Up to 200 Million Yuan Worth of Shares | MT |
ETFs positioned on DaShenLin Pharmaceutical Group Co., Ltd.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.36% | 4 M€ | -2.96% | ||
| 0.07% | 3 M€ | -.--% | - | |
| 0.07% | 1 M€ | +3.49% | - | |
| 0.01% | 4 M€ | -4.41% | - | |
| 0.01% | 2,808 M€ | +5.90% | - | |
| 0.01% | 441 M€ | +4.60% | - | |
| 0.01% | 149 M€ | +2.17% | - | |
| 0.00% | 117 M€ | +1.11% | - | |
| 0.00% | 34 M€ | +2.14% | - | |
| 0.00% | 7 M€ | +1.95% | - | |
| 0.00% | 15 M€ | +11.24% |
DaShenLin Pharmaceutical Group Co Ltd is a China-based company principally engaged in the pharmaceutical retailing business. The Company's primary business includes direct sales and retailing of Chinese and Western medicine, ginseng nourishing herbs and Chinese medicine pieces, health products, medical apparatus and instruments and other commodities. The Company mainly conducts its business within domestic market.
Sector
Drug Retailers
Calendar
2024-04-29
- Q4 2023 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
21.2
CNY
Average target price
33.62
CNY
Spread / Average Target
+58.61%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -14.86% | 3.33B | |
| -32.21% | 15.27B | |
| -31.97% | 10.84B | |
| -30.42% | 6.06B | |
| +8.14% | 6.04B | |
| -11.41% | 5.86B | |
| -0.88% | 4.71B | |
| +52.19% | 4.29B | |
| -12.31% | 3.61B | |
| -6.93% | 3.01B |
- Stock Market
- Equities
- 603233 Stock
- Funds and ETFs DaShenLin Pharmaceutical Group Co., Ltd.
